# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006

Version 6.0 Revision Date 08.02.2013

Print Date 26.04.2013

GENERIC EU MSDS - NO COUNTRY SPECIFIC DATA - NO OEL DATA

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifiers

Product name : Methanol

Product Number : 65550 Brand : Fluka

Index-No. : 603-001-00-X

REACH No. : 01-2119433307-44-XXXX

CAS-No. : 67-56-1

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory chemicals, Manufacture of substances

1.3 Details of the supplier of the safety data sheet

Company : Sigma-Aldrich Chemie GmbH

Industriestrasse 25 CH-9471 BUCHS

Telephone : +41 81-755-2511 Fax : +41 81-756-5449 E-mail address : eurtechserv@sial.com

1.4 Emergency telephone number

Emergency Phone # : +41 81-755-2255

145(CH)

+41 44-251-5151 (Tox-Zentrum)

#### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

# Classification according to Regulation (EC) No 1272/2008

Flammable liquids (Category 2), H225 Acute toxicity, Inhalation (Category 3), H331 Acute toxicity, Dermal (Category 3), H311 Acute toxicity, Oral (Category 3), H301

Specific target organ toxicity - single exposure (Category 1), H370

For the full text of the H-Statements mentioned in this Section, see Section 16.

Classification according to EU Directives 67/548/EEC or 1999/45/EC

F Highly flammable R11

T Toxic R23/24/25, R39/23/24/25

For the full text of the R-phrases mentioned in this Section, see Section 16.

# 2.2 Label elements

### Labelling according Regulation (EC) No 1272/2008

Pictogram

Signal word Danger

Hazard statement(s)

H225 Highly flammable liquid and vapour.

H301 Toxic if swallowed.
H311 Toxic in contact with skin.

H331 Toxic if inhaled.

H370 Causes damage to organs.

Precautionary statement(s)

P210 Keep away from heat/sparks/open flames/hot surfaces. - No smoking.

P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.

P280 Wear protective gloves/ protective clothing.

P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/

physician.

P311 Call a POISON CENTER or doctor/ physician.

Supplemental Hazard

Statements

none

### 2.3 Other hazards

This substance is not considered to be persistent, bioaccumulating nor toxic (PBT)., This substance is not considered to be very persistent nor very bioaccumulating (vPvB).

# **SECTION 3: Composition/information on ingredients**

#### 3.1 Substances

Synonyms : Methyl alcohol

Formula : CH<sub>4</sub>O

Molecular Weight : 32,04 g/mol

CAS-No. : 67-56-1

EC-No. : 200-659-6

Index-No. : 603-001-00-X

Registration number : 01-2119433307-44-XXXX

Hazardous ingredients according to Regulation (EC) No 1272/2008

| Component | Classification  | Concentration |
|-----------|---|---------------|
| Methanol  |   |               |
|           | Flam. Liq. 2; Acute Tox. 3;<br>STOT SE 1; H225, H301 +<br>H311 + H331, H370 | -             |

Hazardous ingredients according to Directive 1999/45/EC

| Component | Classification                          | Concentration |
|-----------|---|---------------|
| Methanol  |   |               |
|           | F, T, R11 - R23/24/25 -<br>R39/23/24/25 | -             |

For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

# **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

#### General advice

Consult a physician. Show this safety data sheet to the doctor in attendance.

#### If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

#### In case of skin contact

Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.

## In case of eye contact

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Fluka - 65550 Page 2 of 17

#### If swallowed

Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

# 4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

## 4.3 Indication of any immediate medical attention and special treatment needed

no data available

# **SECTION 5: Firefighting measures**

# 5.1 Extinguishing media

#### Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

# 5.2 Special hazards arising from the substance or mixture

Carbon oxides

## 5.3 Advice for firefighters

Wear self contained breathing apparatus for fire fighting if necessary.

#### 5.4 Further information

Use water spray to cool unopened containers.

### SECTION 6: Accidental release measures

## 6.1 Personal precautions, protective equipment and emergency procedures

Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations. Vapours can accumulate in low areas. For personal protection see section 8.

## 6.2 Environmental precautions

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

#### 6.3 Methods and materials for containment and cleaning up

Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in container for disposal according to local regulations (see section 13).

#### 6.4 Reference to other sections

For disposal see section 13.

# **SECTION 7: Handling and storage**

# 7.1 Precautions for safe handling

Avoid contact with skin and eves. Avoid inhalation of vapour or mist.

Keep away from sources of ignition - No smoking. Take measures to prevent the build up of electrostatic charge.

For precautions see section 2.2.

### 7.2 Conditions for safe storage, including any incompatibilities

Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed and kept upright to prevent leakage.

### 7.3 Specific end use(s)

A part from the uses mentioned in section 1.2 no other specific uses are stipulated

Fluka - 65550 Page 3 of 17

# **SECTION 8: Exposure controls/personal protection**

## 8.1 Control parameters

# Components with workplace control parameters

# **Derived No Effect Level (DNEL)**

| Delived No Lifect Level (DNLL) |              |                            |              |  |  |  |
|--------------------------------|--------------|----------------------------|--------------|--|--|--|
| Application Area Exposure      |              | Health effect              | Value        |  |  |  |
|                                | routes       |                            |              |  |  |  |
| Workers                        | Inhalation   | Acute local effects        | 260 mg/m3    |  |  |  |
| Workers                        | Inhalation   | Acute systemic effects     | 260 mg/m3    |  |  |  |
| Workers                        | Skin contact | Long-term systemic effects | 40mg/kg BW/d |  |  |  |
| Workers                        | Inhalation   | Long-term systemic effects | 260 mg/m3    |  |  |  |
| Workers                        | Inhalation   | Long-term local effects    | 260 mg/m3    |  |  |  |
| Consumers                      | Skin contact | Acute local effects        | 8mg/kg BW/d  |  |  |  |
| Consumers                      | Inhalation   | Acute local effects        | 50 mg/m3     |  |  |  |
| Consumers                      | Ingestion    | Acute local effects        | 8mg/kg BW/d  |  |  |  |
| Consumers                      | Inhalation   | Acute systemic effects     | 50 mg/m3     |  |  |  |
| Consumers                      | Skin contact | Long-term systemic effects | 8mg/kg BW/d  |  |  |  |
| Consumers                      | Inhalation   | Long-term systemic effects | 50 mg/m3     |  |  |  |
| Consumers                      | Ingestion    | Long-term systemic effects | 8mg/kg BW/d  |  |  |  |
| Consumers                      | Inhalation   | Long-term local effects    | 50 mg/m3     |  |  |  |
| Workers                        | Skin contact | Acute local effects        | 40mg/kg BW/d |  |  |  |

# **Predicted No Effect Concentration (PNEC)**

| Compartment                   | Value       |
|-------------------------------|-------------|
| Soil                          | 23,5 mg/kg  |
| Marine water                  | 15,4 mg/l   |
| Fresh water                   | 154 mg/l    |
| Fresh water sediment          | 570,4 mg/kg |
| Onsite sewage treatment plant | 100 mg/kg   |

# 8.2 Exposure controls

## **Appropriate engineering controls**

Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.

# Personal protective equipment

#### Eye/face protection

Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

## Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.

Full contact

Material: butyl-rubber

Minimum layer thickness: 0,3 mm Break through time: 480 min

Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M)

Splash contact

Material: Nitrile rubber

Minimum layer thickness: 0,4 mm Break through time: 31 min

Fluka - 65550 Page 4 of 17

Material tested:Camatril® (KCL 730 / Aldrich Z677442, Size M)

data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de,

test method: EN374

If used in solution, or mixed with other substances, and under conditions which differ from EN 374. contact the supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It should not be construed as offering an approval for any specific use scenario.

# **Body Protection**

Complete suit protecting against chemicals, Flame retardant antistatic protective clothing, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

## Respiratory protection

Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose combination (US) or type AXBEK (EN 14387) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

# Control of environmental exposure

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

# **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Form: liquid a) Appearance

Colour: colourless

b) Odour pungent

Odour Threshold no data available no data available d) pН

Melting point/freezing

Melting point/range: -98 °C

Initial boiling point and

boiling range

64,7 °C

g) Flash point 9,7 °C - closed cup h) Evapouration rate no data available

i) Flammability (solid, gas) no data available

Upper/lower Upper explosion limit: 36 %(V) flammability or Lower explosion limit: 6 %(V)

explosive limits

Vapour pressure 130,3 hPa at 20,0 °C

> 546,6 hPa at 50,0 °C 169.27 hPa at 25.0 °C

Vapour density 1.11

m) Relative density 0,791 g/mL at 25 °C0,791 g/mL at 20 °C

n) Water solubility completely miscible

o) Partition coefficient: n-

octanol/water

log Pow: -0,77

455,0 °C at 1.013 hPa p) Auto-ignition

temperature

no data available

Decomposition temperature

Fluka - 65550 Page 5 of 17 r) Viscosity no data availables) Explosive properties Not explosive

t) Oxidizing properties The substance or mixture is not classified as oxidizing.

# 9.2 Other safety information

Minimum ignition energy 0,14 mJ Conductivity  $< 1 \mu S/cm$  Relative vapour density 1,11

## **SECTION 10: Stability and reactivity**

## 10.1 Reactivity

no data available

# 10.2 Chemical stability

Stable under recommended storage conditions.

# 10.3 Possibility of hazardous reactions

no data available

#### 10.4 Conditions to avoid

Heat, flames and sparks. Extremes of temperature and direct sunlight.

# 10.5 Incompatible materials

Acid chlorides, Acid anhydrides, Oxidizing agents, Alkali metals, Reducing agents, Acids

# 10.6 Hazardous decomposition products

Other decomposition products - no data available

In the event of fire: see section 5

# **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

## **Acute toxicity**

LDLO Oral - Human - 143 mg/kg

Remarks: Lungs, Thorax, or Respiration:Dyspnea. Ingestion may cause gastrointestinal irritation, nausea, vomiting and diarrhoea.

LD50 Oral - rat - 1.187 - 2.769 mg/kg

LC50 Inhalation - rat - 4 h - 128,2 mg/l

LC50 Inhalation - rat - 6 h - 87,6 mg/l

LD50 Dermal - rabbit - 17.100 mg/kg

## Skin corrosion/irritation

Skin - rabbit

Result: No skin irritation

# Serious eye damage/eye irritation

Eyes - rabbit

Result: No eye irritation

# Respiratory or skin sensitisation

Maximisation Test - guinea pig Does not cause skin sensitisation.

(OECD Test Guideline 406)

## Germ cell mutagenicity

Ames test S. typhimurium Result: negative

Fluka - 65550 Page 6 of 17

in vitro assay fibroblast Result: negative

Mutation in mammalian somatic cells.

Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)

mouse - male and female

Result: negative

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as

probable, possible or confirmed human carcinogen by IARC.

Reproductive toxicity

Damage to fetus not classifiable

Fertility classification not possible from current data.

Specific target organ toxicity - single exposure

Causes damage to organs.

Specific target organ toxicity - repeated exposure

The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**Aspiration hazard** 

No aspiration toxicity classification

**Additional Information** 

RTECS: PC1400000

Methyl alcohol may be fatal or cause blindness if swallowed.

Effects due to ingestion may include:, Headache, Dizziness, Drowsiness, metabolic acidosis, Coma,

Seizures.

Symptoms may be delayed., Damage of the:, Liver, Kidney

Central nervous system - Breathing difficulties - Based on Human Evidence

# **SECTION 12: Ecological information**

# 12.1 Toxicity

Toxicity to fish mortality LC50 - Lepomis macrochirus (Bluegill) - 15.400,0 mg/l - 96 h

NOEC - Oryzias latipes - 7.900 mg/l - 200 h

Toxicity to daphnia and

EC50 - Daphnia magna (Water flea) - > 10.000,00 mg/l - 48 h

other aquatic invertebrates

Toxicity to algae Growth inhibition EC50 - Scenedesmus capricornutum (fresh water algae) -

22.000,0 mg/l - 96 h

12.2 Persistence and degradability

Biodegradability aerobic - Exposure time 5 d

Result: 72 % - rapidly biodegradable

Biochemical Oxygen

600 - 1.120 mg/g

Demand (BOD)

Chemical Oxygen 1.420 mg/g

Demand (COD)

Theoretical oxygen 1.500 mg/g

demand

12.3 Bioaccumulative potential

Bioaccumulation Cyprinus carpio (Carp) - 72 d

at 20 °C - 5 mg/l

Bioconcentration factor (BCF): 1,0

Fluka - 65550 Page 7 of 17

## 12.4 Mobility in soil

Will not adsorb on soil.

### 12.5 Results of PBT and vPvB assessment

This substance is not considered to be persistent, bioaccumulating nor toxic (PBT)., This substance is not considered to be very persistent nor very bioaccumulating (vPvB).

#### 12.6 Other adverse effects

Additional ecological

information

Avoid release to the environment.

Stability in water at 19 °C83 - 91 % - 72 h

Remarks: Hydrolyses on contact with water. Hydrolyses readily.

# **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

#### **Product**

Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal company.

# **Contaminated packaging**

Dispose of as unused product.

# **SECTION 14: Transport information**

14.1 UN number

ADR/RID: 1230 IMDG: 1230 IATA: 1230

# 14.2 UN proper shipping name

ADR/RID: METHANOL IMDG: METHANOL IATA: Methanol

14.3 Transport hazard class(es)

ADR/RID: 3 (6.1) IMDG: 3 (6.1) IATA: 3 (6.1)

14.4 Packaging group

ADR/RID: II IMDG: II IATA: II

14.5 Environmental hazards

ADR/RID: no IMDG Marine pollutant: no IATA: no

### 14.6 Special precautions for user

no data available

# **SECTION 15: Regulatory information**

This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

no data available

# 15.2 Chemical Safety Assessment

A Chemical Safety Assessment has been carried out for this substance.

### **SECTION 16: Other information**

#### Full text of H-Statements referred to under sections 2 and 3.

Acute Tox. Acute toxicity
Flam. Liq. Flammable liquids

H225 Highly flammable liquid and vapour.

H301 Toxic if swallowed.

H301 + H311 + Toxic if swallowed, in contact with skin or if inhaled

Fluka - 65550 Page 8 of 17

H331

H311 Toxic in contact with skin.

H331 Toxic if inhaled.

H370 Causes damage to organs.

# Full text of R-phrases referred to under sections 2 and 3

F Highly flammable

T Toxic

R11 Highly flammable.

R23/24/25 Toxic by inhalation, in contact with skin and if swallowed.

R39/23/24/25 Toxic: danger of very serious irreversible effects through inhalation, in contact with

skin and if swallowed.

# **Further information**

Copyright 2013 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

Fluka - 65550 Page 9 of 17

Annex: Exposure scenario

#### Identified uses:

#### Use: Used as chemical intermediate

SU 3: Industrial uses: Uses of substances as such or in preparations at industrial sites

**SU 3, SU9:** Industrial uses: Uses of substances as such or in preparations at industrial sites, Manufacture of fine chemicals

PC19: Intermediate

PROC1: Use in closed process, no likelihood of exposure

PROC2: Use in closed, continuous process with occasional controlled exposure

PROC3: Use in closed batch process (synthesis or formulation)

PROC4: Use in batch and other process (synthesis) where opportunity for exposure arises

**PROC8b:** Transfer of substance or preparation (charging/ discharging) from/ to vessels/ large containers at dedicated facilities

**PROC15:** Use as laboratory reagent

**ERC1, ERC4, ERC6a:** Manufacture of substances, Industrial use of processing aids in processes and products, not becoming part of articles, Industrial use resulting in manufacture of another substance (use of intermediates)

## **Use: Formulation of preparations**

SU 3: Industrial uses: Uses of substances as such or in preparations at industrial sites

SU 10: Formulation [mixing] of preparations and/ or re-packaging (excluding alloys)

PROC2: Use in closed, continuous process with occasional controlled exposure

PROC3: Use in closed batch process (synthesis or formulation)

PROC4: Use in batch and other process (synthesis) where opportunity for exposure arises

**PROC8b:** Transfer of substance or preparation (charging/ discharging) from/ to vessels/ large containers at dedicated facilities

**PROC9:** Transfer of substance or preparation into small containers (dedicated filling line, including weighing)

PROC15: Use as laboratory reagent

**ERC2:** Formulation of preparations

## Use: Industrial use of processing aids in processes and products, not becoming part of articles

SU 3: Industrial uses: Uses of substances as such or in preparations at industrial sites

**SU 3, SU9:** Industrial uses: Uses of substances as such or in preparations at industrial sites, Manufacture of fine chemicals

PC20: Products such as ph-regulators, flocculants, pre-cipitants, neutralization agents

PC21: Laboratory chemicals

PROC1: Use in closed process, no likelihood of exposure

PROC2: Use in closed, continuous process with occasional controlled exposure

PROC3: Use in closed batch process (synthesis or formulation)

PROC4: Use in batch and other process (synthesis) where opportunity for exposure arises

**PROC8b:** Transfer of substance or preparation (charging/ discharging) from/ to vessels/ large containers at dedicated facilities

**PROC9:** Transfer of substance or preparation into small containers (dedicated filling line, including weighing)

PROC10: Roller application or brushing

**PROC15:** Use as laboratory reagent

**ERC4, ERC6b:** Industrial use of processing aids in processes and products, not becoming part of articles, Industrial use of reactive processing aids

#### Use: Used as laboratory reagent.

SU 22: Professional uses: Public domain (administration, education, entertainment, services, craftsmen)

**SU 3, SU 22, SU24:** Industrial uses: Uses of substances as such or in preparations at industrial sites, Professional uses: Public domain (administration, education, entertainment, services, craftsmen),

Scientific research and development

PC19: Intermediate

PC20: Products such as ph-regulators, flocculants, pre-cipitants, neutralization agents

PC21: Laboratory chemicals

Fluka - 65550 Page 10 of 17

**PROC10:** Roller application or brushing **PROC15:** Use as laboratory reagent

**ERC4**, **ERC6a**, **ERC6b**: Industrial use of processing aids in processes and products, not becoming part of articles, Industrial use resulting in manufacture of another substance (use of intermediates), Industrial use of reactive processing aids

# 1. Short title of Exposure Scenario: Used as chemical intermediate

Main User Groups : SU 3
Sectors of end-use : SU 3, SU9
Chemical product category : PC19

Process categories : PROC1, PROC2, PROC3, PROC4, PROC8b, PROC15

Environmental Release Categories : ERC1, ERC4, ERC6a:

## 2. Exposure scenario

# 2.1 Contributing scenario controlling environmental exposure for: ERC1, ERC4, ERC6a

### **Product characteristics**

Concentration of the Substance in : Covers the percentage of the substance in the product up to

Mixture/Article 100 % (unless stated differently).

# 2.2 Contributing scenario controlling worker exposure for: PROC1, PROC2, PROC3, PROC4, PROC8b, PROC15, PC19

#### **Product characteristics**

Concentration of the Substance in : Covers the percentage of the substance in the product up to

Mixture/Article 100 % (unless stated differently).

Physical Form (at time of use) : High volatile liquid

Frequency and duration of use

Application duration : > 4 h

Frequency of use : 220 days/year

# Other operational conditions affecting workers exposure

Outdoor / Indoor : Indoor

## **Technical conditions and measures**

Good work practice required., Use only in area provided with appropriate exhaust ventilation.

## Organisational measures to prevent /limit releases, dispersion and exposure

Ensure operatives are trained to minimise exposures.

# Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374., For personal protection see section 8.

## 3. Exposure estimation and reference to its source

#### **Environment**

A chemical safety assessment was performed according REACH Article 14(3), Annex I, sections 3 (Environmental Hazard assessment) and 4 (PBT/vPvB Assessment). As no hazard was identified, an exposure assessment and risk characterisation is not necessary (REACH Annex I section 5.0).

#### Workers

| Contributing<br>Scenario | Exposure<br>Assessment<br>Method | Specific conditions                  | Value      | Level of<br>Exposure | RCR*  |
|--------------------------|----------------------------------|--------------------------------------|------------|----------------------|-------|
| PROC1                    | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Inhalation | 0,01 mg/m3           | 0     |
| PROC1                    | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Dermal     | 0,34 mg/kg<br>BW/d   | 0,009 |

Fluka - 65550 Page 11 of 17

| PROC2  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 6,67 mg/m3          | 0,026 |
|--------|------------|--------------------------------------|------------|---------------------|-------|
| PROC2  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 13,33 mg/kg<br>BW/d | 0,333 |
| PROC3  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 0,34 mg/kg<br>BW/d  | 0,009 |
| PROC3  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 13,33 mg/m3         | 0,051 |
| PROC4  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 6,86 mg/kg<br>BW/d  | 0,172 |
| PROC4  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 13,33 mg/m3         | 0,051 |
| PROC8b | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 6 mg/m3             | 0,023 |
| PROC8b | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 6,86 mg/kg<br>BW/d  | 0,172 |
| PROC15 | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 0,34 mg/kg<br>BW/d  | 0,009 |
| PROC15 | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 6,67 mg/m3          | 0,026 |

<sup>\*</sup>Risk characterisation ratio

# 4. Guidance to Downstream User to evaluate whether he works inside the boundaries set by the Exposure Scenario

Please refer to the following documents: ECHA Guidance on information requirements and chemical safety assessment Part D: Exposure Scenario Building, Part E: Risk Characterisation and Part G: Extending the SDS; VCI/Cefic REACH Practical Guides on Exposure Assessment and Communications in the Supply Chain; CEFIC Guidance Specific Environmental Release Categories (SPERCs).

# 1. Short title of Exposure Scenario: Formulation of preparations

Main User Groups : SU 3
Sectors of end-use : SU 10

Process categories : PROC2, PROC3, PROC4, PROC8b, PROC9, PROC15

Environmental Release Categories : ERC2:

### 2. Exposure scenario

# 2.1 Contributing scenario controlling environmental exposure for: ERC2

#### **Product characteristics**

Concentration of the Substance in : Covers the percentage of the substance in the product up to Mixture/Article : 100 % (unless stated differently).

10. O and the state of the stat

# 2.2 Contributing scenario controlling worker exposure for: PROC2, PROC3, PROC4, PROC8b, PROC9, PROC15

# **Product characteristics**

Concentration of the Substance in

Mixture/Article

100 % (unless stated differently).
of use) : High volatile liquid

Physical Form (at time of use) : High volatile liqu

Fluka - 65550 Page 12 of 17

: Covers the percentage of the substance in the product up to

# Frequency and duration of use

Application duration : > 4 h

Frequency of use : 220 days/year

# Other operational conditions affecting workers exposure

Outdoor / Indoor : Indoor

#### Technical conditions and measures

Use only in area provided with appropriate exhaust ventilation., Good work practice required.

# Organisational measures to prevent /limit releases, dispersion and exposure

Ensure operatives are trained to minimise exposures.

# Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374., For personal protection see section 8.

## 3. Exposure estimation and reference to its source

### **Environment**

A chemical safety assessment was performed according REACH Article 14(3), Annex I, sections 3 (Environmental Hazard assessment) and 4 (PBT/vPvB Assessment). As no hazard was identified, an exposure assessment and risk characterisation is not necessary (REACH Annex I section 5.0).

# **Workers**

| Contributing<br>Scenario | Exposure<br>Assessment<br>Method | Specific conditions                  | Value      | Level of Exposure   | RCR*  |
|--------------------------|----------------------------------|--------------------------------------|------------|---------------------|-------|
| PROC2                    | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Inhalation | 6,67 mg/m3          | 0,026 |
| PROC2                    | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Dermal     | 13,33 mg/kg<br>BW/d | 0,333 |
| PROC3                    | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Inhalation | 13,33 mg/m3         | 0,051 |
| PROC3                    | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Dermal     | 0,34 mg/kg<br>BW/d  | 0,009 |
| PROC4                    | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Inhalation | 13,33 mg/m3         | 0,051 |
| PROC4                    | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Dermal     | 6,86 mg/kg<br>BW/d  | 0,172 |
| PROC8b                   | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Inhalation | 6 mg/m3             | 0,023 |
| PROC8b                   | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Dermal     | 6,86 mg/kg<br>BW/d  | 0,172 |
| PROC9                    | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Inhalation | 26,67 mg/m3         | 0,103 |
| PROC9                    | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Dermal     | 6,86 mg/kg<br>BW/d  | 0,172 |
| PROC15                   | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Inhalation | 6,67 mg/m3          | 0,026 |
| PROC15                   | ECETOC TRA                       | With Local                           | Dermal     | 0,34 mg/kg          | 0,009 |

Fluka - 65550 Page 13 of 17

|  | Exhaust     | BW/d |  |
|--|-------------|------|--|
|  | Ventilation |      |  |

<sup>\*</sup>Risk characterisation ratio

# 4. Guidance to Downstream User to evaluate whether he works inside the boundaries set by the Exposure Scenario

Please refer to the following documents: ECHA Guidance on information requirements and chemical safety assessment Part D: Exposure Scenario Building, Part E: Risk Characterisation and Part G: Extending the SDS; VCI/Cefic REACH Practical Guides on Exposure Assessment and Communications in the Supply Chain; CEFIC Guidance Specific Environmental Release Categories (SPERCs).

# 1. Short title of Exposure Scenario: Industrial use of processing aids in processes and products, not becoming part of articles

Main User Groups : SU 3
Sectors of end-use : SU 3, SU9
Chemical product category : PC20, PC21

Process categories : PROC1, PROC2, PROC3, PROC4, PROC8b, PROC9,

PROC10, PROC15

Environmental Release Categories : ERC4, ERC6b:

## 2. Exposure scenario

# 2.1 Contributing scenario controlling environmental exposure for: ERC4, ERC6b

#### **Product characteristics**

Concentration of the Substance in : Covers the percentage of the substance in the product up to

Mixture/Article 100 % (unless stated differently).

# 2.2 Contributing scenario controlling worker exposure for: PROC1, PROC2, PROC3, PROC4, PROC8b, PROC9, PROC10, PROC15, PC20, PC21

#### **Product characteristics**

Concentration of the Substance in : Covers the percentage of the substance in the product up to

Mixture/Article 100 % (unless stated differently).

Physical Form (at time of use) : High volatile liquid

Frequency and duration of use

Application duration : > 4 h

Frequency of use : 220 days/year

### Other operational conditions affecting workers exposure

Outdoor / Indoor : Indoor

#### Technical conditions and measures

Use only in area provided with appropriate exhaust ventilation., Good work practice required.

# Organisational measures to prevent /limit releases, dispersion and exposure

Ensure operatives are trained to minimise exposures.

# Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374., For personal protection see section 8.

# 3. Exposure estimation and reference to its source

#### **Environment**

A chemical safety assessment was performed according REACH Article 14(3), Annex I, sections 3 (Environmental Hazard assessment) and 4 (PBT/vPvB Assessment). As no hazard was identified, an exposure assessment and risk characterisation is not necessary (REACH Annex I section 5.0).

# **Workers**

| Contributing Exposure Specific Conditions | Value | Level of Exposure | RCR* |
|---|-------|-------------------|------|
|---|-------|-------------------|------|

Fluka - 65550 Page 14 of 17

|        | Method     |                                      |            |                     |       |
|--------|------------|--------------------------------------|------------|---------------------|-------|
| PROC1  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 0,34 mg/kg<br>BW/d  | 0,009 |
| PROC1  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 0,01 mg/m3          | 0     |
| PROC2  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 6,67 mg/m3          | 0,026 |
| PROC2  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 13,33 mg/kg<br>BW/d | 0,333 |
| PROC3  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 13,33 mg/m3         | 0,051 |
| PROC3  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 0,34 mg/kg<br>BW/d  | 0,009 |
| PROC4  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 6,86 mg/kg<br>BW/d  | 0,172 |
| PROC4  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 13,33 mg/m3         | 0,051 |
| PROC8b | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 6,86 mg/kg<br>BW/d  | 0,172 |
| PROC8b | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 6 mg/m3             | 0,023 |
| PROC9  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 6,86 mg/kg<br>BW/d  | 0,172 |
| PROC9  | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 26,67 mg/m3         | 0,103 |
| PROC10 | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 53,33 mg/m3         | 0,205 |
| PROC10 | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 21,94 mg/kg<br>BW/d | 0,549 |
| PROC15 | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Inhalation | 6,67 mg/m3          | 0,026 |
| PROC15 | ECETOC TRA | With Local<br>Exhaust<br>Ventilation | Dermal     | 0,34 mg/kg<br>BW/d  | 0,009 |

<sup>\*</sup>Risk characterisation ratio

# 4. Guidance to Downstream User to evaluate whether he works inside the boundaries set by the Exposure Scenario

Please refer to the following documents: ECHA Guidance on information requirements and chemical safety assessment Part D: Exposure Scenario Building, Part E: Risk Characterisation and Part G: Extending the SDS; VCI/Cefic REACH Practical Guides on Exposure Assessment and Communications in the Supply Chain; CEFIC Guidance Specific Environmental Release Categories (SPERCs).

Fluka - 65550 Page 15 of 17

## 1. Short title of Exposure Scenario: Used as laboratory reagent.

Main User Groups : SU 22

Sectors of end-use : SU 3, SU 22, SU24
Chemical product category : PC19, PC20, PC21
Process categories : PROC10, PROC15
Environmental Release Categories : ERC4, ERC6a, ERC6b:

#### 2. Exposure scenario

## 2.1 Contributing scenario controlling environmental exposure for: ERC4, ERC6a, ERC6b

#### **Product characteristics**

Concentration of the Substance in : Covers the percentage of the substance in the product up to

Mixture/Article 100 % (unless stated differently).

### 2.2 Contributing scenario controlling worker exposure for: PROC10, PROC15, PC19, PC20, PC21

# **Product characteristics**

Concentration of the Substance in : Covers the percentage of the substance in the product up to

Mixture/Article 100 % (unless stated differently).

Physical Form (at time of use) : High volatile liquid

Frequency and duration of use

Application duration : > 4 h

Frequency of use : 220 days/year

# Other operational conditions affecting workers exposure

Outdoor / Indoor : Indoor

#### Technical conditions and measures

Use only in area provided with appropriate exhaust ventilation., Good work practice required.

### Organisational measures to prevent /limit releases, dispersion and exposure

Ensure operatives are trained to minimise exposures.

# Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374., For personal protection see section 8.

## 3. Exposure estimation and reference to its source

## **Environment**

A chemical safety assessment was performed according REACH Article 14(3), Annex I, sections 3 (Environmental Hazard assessment) and 4 (PBT/vPvB Assessment). As no hazard was identified, an exposure assessment and risk characterisation is not necessary (REACH Annex I section 5.0).

#### Workers

| Contributing<br>Scenario | Exposure<br>Assessment<br>Method | Specific conditions                  | Value      | Level of<br>Exposure | RCR*  |
|--------------------------|----------------------------------|--------------------------------------|------------|----------------------|-------|
| PROC10                   | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Inhalation | 53,33 mg/m3          | 0,205 |
| PROC10                   | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Dermal     | 21,94 mg/kg<br>BW/d  | 0,549 |
| PROC15                   | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Inhalation | 6,67 mg/m3           | 0,026 |
| PROC15                   | ECETOC TRA                       | With Local<br>Exhaust<br>Ventilation | Dermal     | 0,34 mg/kg<br>BW/d   | 0,009 |

Fluka - 65550 Page 16 of 17

\*Risk characterisation ratio

# 4. Guidance to Downstream User to evaluate whether he works inside the boundaries set by the Exposure Scenario

Please refer to the following documents: ECHA Guidance on information requirements and chemical safety assessment Part D: Exposure Scenario Building, Part E: Risk Characterisation and Part G: Extending the SDS; VCI/Cefic REACH Practical Guides on Exposure Assessment and Communications in the Supply Chain; CEFIC Guidance Specific Environmental Release Categories (SPERCs).

Fluka - 65550 Page 17 of 17